Webinar on demand
Webinar on demand
High-content analysis of disease models and toxicology studies using C. elegans
High-content analysis of disease models and toxicology studies using C. elegans
vivoChip - The next generation of microfluidic screening solutions
vivoChip enables rapid immobilization and high-resolution imaging of C. elegans
High-resolution imaging of entire germline organization
vivoChip-96x: The first large-scale screening platform for C. elegans
Webinar on demand
Webinar on demand
High-content analysis of disease models and toxicology studies using C. elegans
High-content analysis of disease models and toxicology studies using C. elegans
Happy Holidays and a prosperous 2021 from the Newormics team!
Newormics offers advanced microfluidic devices for high-throughput and high-content screening of small animal models and 3D tissue organoids.
We also provide toxicology services and solutions.
Dr. Lotti Brose
Pierce-Shimomura Lab, University of Texas at Austin
Joseph Liang
Rankin lab, University of British Columbia
Steven Ban
Saul Kato Lab, UCSF
Nikhil Mishra
Conradt Lab, LMU Munich
Dr. Sangeetha Iyer
Director of Preclinical Development, Perlara
Newormics awarded SBIR Phase II grant from NIMH
Newormics is excited to announce it has been awarded a $2.25M Phase II SBIR grant from the National Institutes of Health/National Institute of Mental Health (NIMH) for the continued development of the company’s in vivo imaging and screening technologies.
Newormics Announces Intent to Grant Utility Patent on the vivoChip by the European Patent Office
Newormics LLC, a developer of the first high-throughput, high-content screening platforms for use with in vivo small animal models, announced that the European Patent Office (EPO) intends to grant a patent covering the vivoChip® technology, the device design and use for C. elegans studies.